Tissue Regenix Group secures US sales deals

York Press: Tissue Regenix Group secures US sales deals Tissue Regenix Group secures US sales deals

MEDICAL device specialist Tissue Regenix Group has secured seven independent regional sales distribution agreements in the United States.

The moves comes as the business, based at the Biocentre in Heslington, looks to launch its first commercial products in the US market early next year.

The regional distributors represent more than 40 sales representatives that will actively promote Tissue Regenix’s DermaPure product into acute care hospitals, Veteran Affairs hospitals and institutions as well as long-term acute care hospitals in the US.

DermaPure works by taking human donor skin and removing the DNA and cells, using Tissue Regenix’s patented dCELL process to leave a natural biological scaffold to aid natural healing.

With the aim of targeting all the states within the US, Tissue Regenix says it intends to sign further distribution agreements to ensure sales coverage exists in all US metropolitan areas by the end 2014.

Tissue Regenix established its USA subsidiary, Tissue Regenix Wound Care Inc, in November 2012, as part of its commercialisation strategy for its dCELL technology platform.

Greg Bila, president of Tissue Regenix Wound Care Inc, said: “These agreements allow us to launch our institutional sales strategy, and we are working hard with the distributors to bring the product to market. With a significant distribution footprint now in place across the US, we remain steadily on course for the North American commercial launch of DermaPure in 2014.”


Comments are closed on this article.


About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree